In the Boardroom
Refine Search
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Pharmaceutical
Anthony Harnden has been appointed as the new chair of the UK’s Medicine and Healthcare products Regulatory Agency (MHRA). 20 November 2024
Biotechnology
Mirai Bio has announced the appointment of Jens Vogel as the company’s president and chief operating officer (COO). 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Pharmaceutical
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
Biotechnology
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
Biotechnology
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
Pharmaceutical
US ophthalmology specialist Ocular Therapeutix announced that Namrata Saroj has joined the Company on a full-time basis as chief business officer (CBO). Dr Saroj previously served as development strategy consultant to Ocular since February 2024. 14 November 2024
Biotechnology
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
Biotechnology
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Biotechnology
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Biotechnology
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Biotechnology
US biotech major Biogen revealed it has appointed Daniel Quirk as chief medical officer and head of medical affairs. 29 October 2024
Pharmaceutical
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024
Biotechnology
AAVantgarde has announced the appointment of Lauren Kaskiel as chief business officer (CBO). 22 October 2024
Pharmaceutical
Privately-held Scotland-based EnteroBiotix has announced the appointments of Dr James Barnes as chief operating officer (COO) and Chris Lea as chief financial officer (CFO). 1 February 2024
Biotechnology
Danish biotech Ascendis Pharma today announced the formation and launch with Frazier Life Sciences of Eyconis Inc, a separate company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally. 30 January 2024
Pharmaceutical
E Merck KG, the company through which the Merck family holds around 70% of German pharma and life sciences company Merck KGaA, today announced the results of its regular board elections held this past weekend. 29 January 2024
Biotechnology
Osivax, a French biopharma developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, has named Nicola Groth its new chief medical officer (CMO). 26 January 2024
Biotechnology
Cellular Origins, a part of TTP Company, focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies, today announced the appointment of Peter Crossley as chief operating officer (COO). 25 January 2024
Pharmaceutical
AI specialist BenevolentAI today announced the appointment of Dr Joerg Moeller as chief executive and executive board member with immediate effect. 24 January 2024
Pharmaceutical
Shares of US radiopharmaceuticals-focussed Lantheus Holdings (Nasdaq: LNTH) were down 5.4% at $51.88 by late morning today, as it announced the appointment of Brian Markison, current board chairman and industry veteran, to the position of chief executive (CEO), effective as of March 1, 2024. 23 January 2024
Biotechnology
This week in The Pharma Letter Podcast, we are speaking with the chief executive of British drug development company Ellipses Pharma. 23 January 2024
Biotechnology
French biotech Transgene has appointed James Wentworth as chief business officer, with immediate effect. 23 January 2024
Pharmaceutical
US clinical-stage pharma company Apnimed has announced that Graham Goodrich has joined the company as chief commercial officer. 23 January 2024
Biotechnology
Oxford Nanopore Technologies, a UK company delivering nanopore-based molecular sensing technology, has announced the expansion of its leadership team. 22 January 2024
Biotechnology
Last Tuesday, US biotech Aclaris Therapeutics announced that its chief executive would be stepping down and that the company is undertaking a review of its business and development of its dermatology candidates ATI-1777 and ATI-2138. US biotech Allakos suffered a further set back with its lirentelimab in trials for dermatitis and urticaria, leading to a decision to discontinue development. US biotech BridgeBio Pharma has agreed a deal to add up to $1.25 billion to its cash pile in a bid to progress its cardiovascular candidate acoramidis. Dutch biotech argenx gained Japanese approval for its myasthenia gravis drug Vyvdura/Vyvgart. 21 January 2024
Biotechnology
UK-based Avacta Group announced that Dr Christina Coughlin, on February 1, will take up the position of head of research and development. 19 January 2024
Biotechnology
US clinical stage developer Immunitas Therapeutics today announced the appointment of Annalisa D’Andrea as its chief scientific officer (CSO). 18 January 2024
Biotechnology
San Diego, California-based Tr1X has announced its emergence from stealth with a $75 million Series A financing. 18 January 2024
Biotechnology
With the aim of boosting is leadership team, clinical-stage biotech Zura Bio today announced the appointments of Robert Lisicki as president and chief operating officer, and Kiran Nistala as executive vice president development and chief medical officer, to the executive leadership team. 17 January 2024
Biotechnology
Shares of US clinical-stage biotech Aclaris Therapeutics shot up as much as 40% to $1.21 in early trading today, after it announced leadership changes and that it is undertaking a strategic review of its business. 16 January 2024
Biotechnology
New York, USA-based rare neurological disease drug developer Neurogene has announced the appointment of Julie Jordan as its chief medical officer (CMO). 16 January 2024
Biotechnology
California, USA-based biotech start-up TORL BioTherapeutics has appointed of Mark Alles, currently executive chairman, to the additional post of chief executive (CEO). 12 January 2024
Biotechnology
Rob Scott has been appointed chief medical officer (CMO) of Abionyx Pharma, a French biotech focused on the discovery and development of innovative therapies based on the world's only recombinant apoA-I. 10 January 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze